Phase 2 N=9 MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Merkel Cell Carcinoma
Primary: MLN01283 Maximum Tolerated Dose (MTD) [Phase I] — 3 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Recurrent Merkel Cell Carcinoma · Stage III Merkel Cell Carcinoma AJCC v7 · Stage IIIA Merkel Cell Carcinoma AJCC v7
Primary: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation…
Phase 2 N=204 Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Carcinoma, Merkel Cell
Primary: Part A: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 — 10; 19; 9; 0…
Phase 3 N=55 Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Merkel Cell Carcinoma
Primary: Objective Response Rate (ORR) — 49.1 Percentage of participants
Phase 2 N=9 Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
Advanced Merkel Cell Carcinoma · Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) — 7.5; 5.5 months
Phase 2 N=107 A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Metastatic Merkel Cell Carcinoma
Primary: Objective Response Rate (ORR) — 52.3 percentage of participants
Phase 2 N=15 IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Merkel Cell Carcinoma
Primary: Percentage of Participants Who Experienced At Least 2-Fold Increase in Expression of IL-12 Protein in the Tumor Tissue After Intratumoral (IT) pIL-12 Injections and In…
Phase 2 N=17 Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Medullary Thyroid Cancer (MTC)
Primary: Clinical Response — 0; 0 Participants
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=11 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Recurrent Skin Carcinoma · Skin Squamous Cell Carcinoma
Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants
Phase 2 N=16 Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate (ORR) — 44; 29 Percentage of participants
Phase 2 N=21 Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) — 0; 0 Participants
Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Phase 2 N=34 Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Metastatic Adenoid Cystic Carcinoma · Progressive Disease · Recurrent Adenoid Cystic Carcinoma
Primary: Assess the Objective Response Rate (ORR) to Axitinib and Avelumab Combination According to RECIST 1.1 Criteria. — 18 percentage of participants
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=19 A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Melanoma · Merkel Cell Carcinoma · Other Solid Tumors
Primary: Best Response — 1; 1; 0; 0 Participants
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 2 N=24 Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
Recurrent Mycosis Fungoides and Sezary Syndrome · Refractory Mycosis Fungoides and Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7
Primary: Objective Response Rate (ORR), Defined as a Confirmed Partial Response (PR) or Complete Response (CR) Using Global Assessment Standard Response Criteria for Mycosis…
Phase 3 N=450 Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Carcinoma, Squamous Cell
Primary: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy — 53.3; 53.7 Months — p=0.07243
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=48 Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma, Head and Neck
Primary: Tumor Response Rate (TRR) — 3; 0 Participants
Phase 2 N=9 Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
Mycosis Fungoides · Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
Primary: Proportion of Overall Cutaneous Responders at Their 9th or Final Cycle (Cutaneous Complete Response [CR], Cutaneous 90 Response [CR90] or Cutaneous Partial Response…
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 2 N=39 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Phase 1 N=25 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Metastatic Malignant Neoplasm in the Brain · Metastatic Melanoma · Mucosal Melanoma
Primary: Dose Limiting Toxicities — 0; 0; 0 Participants
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=35 Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
Non-Small Cell Lung Cancer
Primary: Phase Ib: Maximum Tolerated Dose — 4; 200 mg
Phase 2 N=76 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Breast Cancer · Chest Wall Disease
Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants